Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Estramustine and Vinorelbine in Hormone-Refractory Prostate Cancer
NCT00151086Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2001
- Primary completion
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine in prostate cancer (PCa), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Tolerable Dose of Vinorelbine in Combination with Estramustine. Started Dec 2001; status: completed.
02
Drugs
vinorelbine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00151086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151086.